EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter open-label 2-arm cohort study comparing a four-drug nevirapine-containing antiviral therapy versus a three-drug combination without nevirapine



Multicenter open-label 2-arm cohort study comparing a four-drug nevirapine-containing antiviral therapy versus a three-drug combination without nevirapine



Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 516




(PDF 0-2 workdays service: $29.90)

Accession: 035349860

Download citation: RISBibTeXText



Related references

Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study. Clinical Therapeutics 33(9): 1308-1320, 2012

Bioavailability of Extended-Release Nevirapine 4 and 3 mg in HIV-1 A Multicenter, Open-Label Study. 2011

Factors related to virological failure in a cohort of injecting drug users treated with a combination therapy including two nucleoside reverse transcriptase inhibitors and nevirapine. AIDS (Hagerstown) 14(Supplement 4): S38, October, 2000

Drug-resistant mutation patterns in CRF01_AE cases that failed d4T+3TC+nevirapine fixed-dosed, combination treatment: Follow-up study from the Lampang cohort. Antiviral Research 87(1): 22-29, 2010

Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study. HIV Clinical Trials 3(3): 177-185, 2002

Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proceedings of the National Academy of Sciences of the United States of America 108(22): 9202-9207, 2011

Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. Journal of Acquired Immune Deficiency Syndromes 35(5): 492-502, 2004

A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals. Journal of Acquired Immune Deficiency Syndromes 66(2): 140-147, 2014

Notes on the road to perfection; use of nevirapine in combination antiretroviral therapy for children with perinatal nevirapine exposure. Aids 29(13): 1715-1716, 2016

Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clinical Infectious Diseases 33(9): 1595-1597, 2001

The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study. Journal of Acquired Immune Deficiency Syndromes 27(2): 124-129, 2001

The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy. Aids Research and Therapy 11(): 36-36, 2014

Nevirapine patch testing in Thai human immunodeficiency virus infected patients with nevirapine drug hypersensitivity. Contact Dermatitis 77(6): 379-384, 2017

Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet. Infectious Diseases 12(7): 521-530, 2012

A open-label, randomized, comparative study of stavudine + didanosine + indinavir versus d4T + ddI + nevirapine in treatment of HIV-infected naive patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 280, 2000